Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Logothetis

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
Iscience|June 11, 2020
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder CancerGuoliang Yang, Jolanta Bondaruk, David Cogdell, et al.
JAMA Network Open|August 30, 2021
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint InhibitorsPavlos Msaouel, Clara Oromendia, Arlene O Siefker-Radtke, et al.
Biomarker Research|November 10, 2024
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working GroupHoward I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Cancers|December 10, 2021
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal StudiesDaniel D Shapiro, Melinda Soeung, Luigi Perelli, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
Iscience|June 11, 2020
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder CancerGuoliang Yang, Jolanta Bondaruk, David Cogdell, et al.
JAMA Network Open|August 30, 2021
Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint InhibitorsPavlos Msaouel, Clara Oromendia, Arlene O Siefker-Radtke, et al.
Biomarker Research|November 10, 2024
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillanceJustin R Gregg, Lisa Newcomb, Ranran Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2004
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working GroupHoward I Scher, Mario Eisenberger, Anthony V D'Amico, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Cancer|November 20, 2019
Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trendsChad Tang, Karen E Hoffman, Pamela K Allen, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Cancers|December 10, 2021
Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal StudiesDaniel D Shapiro, Melinda Soeung, Luigi Perelli, et al.
Pageof 9